Henlius Swallows Bitter Pill in Watered-Down Licensing Deal
The innovative drug company will receive less benefits from an existing licensing deal after revisions to reflect high R&D costs Key Takeaways: Henlius Biotech will receive up to $11 million…
2696.HK
Recent Articles
RELATED ARTICLES
-
Henlius finds elixir in first profits, scraps A-share IPO
2696.HK
-
HBM gets health boost from drug licensing deals
2142.HK
-
Everest reaches new heights on growing drug sales
1952.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Akeso marks profit milestone with swift rights issue
9926.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
Discover hidden China stock gems in our weekly newsletter